IQVIA is an American multinational company that combines health information technology and clinical research services. It was formed in 2016 through the merger of Quintiles and IMS Health and is headquartered in Durham, North Carolina.
AI could compress drug development from 10-15 years to as little as six years, accelerating discovery and reducing late-stage trial failures. However, clinical trial execution remains heavily dependent on human oversight, with AI estimated to cut costs only 10-15% while facing regulatory and liability constraints. Major pharma companies like Gilead are investing in AI research centers despite practical limitations in trial implementation.
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
Medicus Pharma reported Phase 2 SKNJCT-003 topline data showing 73% clinical clearance and 40% histological clearance at Day 57 in the 200μg cohort. Separately, the FDA cleared the company to begin a Phase 2b dose optimization study for Teverelix in advanced prostate cancer.
Novo Nordisk plans to expand its Athlone facility in Ireland to produce Wegovy for non-US markets and will launch lower-cost vials in the US in 2026, responding to aggressive pricing from Eli Lilly as the company forecasts a 5-13% decline in revenue and operating profit.
Eli Lilly has accumulated $1.5 billion in pre-launch inventory of its experimental oral weight-loss drug orforglipron ahead of an expected FDA decision in April, up from $550 million last year.
The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.
